Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

Clinical and Translational Oncology

Volumn 16, Issue 10, 2014, Pages 931-934

  Lopez Gonzalez A ^a   Salas, C ^b   Provencio, M ^b   Cordoba M ^b   Gamallo, C ^c  

^a Complejo Asistencial Universitario de León   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Aldehyde dehydrogenase; Lung cancer; Nuclear expression

Indexed keywords

EID: 84896410049     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1173-y     Document Type: Article

References (14)

1. Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225–33.
2. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38:331–6.
3. Sullivan J, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor iniaition, progresión, and targeted therapy. Cancer Metastasis Rev. 2010;29:61–72.
4. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7:330–8.
5. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer item and progenitor cells. Stem Cells Dev. 2009;18(1):17–25.
6. Yoshida A, Hsu LC, Davé V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 1992;46:239–44.
7. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancer are characterized by negative estrógeno receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100:1062–8.
8. Charape-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1 positive cancer item cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55.
9. Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77:162–7.
10. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, et al. Aldehyde dehydrogenase 1-positive cell population is enriched in tumor-initiating cells and associated with progresión of bladder cancer. Cancer Epidemiol Biomark Prev. 2010;19:327–37.
11. Stagos D, Chen Y, Cantore M, Jester JV, Vasiliou V. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15:211–8.
12. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59(3):340–9.
13. Stagos D, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15:21–218.
14. Pappa A, Brown D, Koutalos Y, DeGregori J, White C, Vasiliou V. Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epitelial cells. J Biol Chem. 2005;280:27998–8006.